low - Clinical trial timelines and FDA regulatory processes operate independently of GDP cycles. However, financing environment for biotech correlates with risk appetite during economic expansions versus contractions. Recession periods typically compress biotech valuations and reduce access to capital markets, creating existential risk for pre-revenue companies dependent on equity raises.

High sensitivity through valuation multiple compression. Pre-revenue biotechs are discounted cash flow stories with revenues 5-10 years out. Rising rates increase discount rates applied to distant future cash flows, disproportionately impacting present value. Additionally, higher rates reduce speculative capital flows into high-risk biotech sector. The company's negative cash flow makes it dependent on capital markets access, which tightens materially when rates rise and risk-free alternatives become attractive.

growth - Attracts high-risk tolerance biotech specialists, hedge funds with event-driven strategies around clinical catalysts, and venture capital crossover funds. The pre-revenue profile with binary clinical outcomes appeals to investors seeking asymmetric risk/reward with 5-10x upside potential on successful development versus total loss on failure. Not suitable for value or income investors given negative cash flow and no dividend potential. Momentum traders enter around clinical catalyst dates.